drugset / Trial / NCT00300040

Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia

NCT00300040

Phase 2 Terminated 16 enrolled Biopure Corporation
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to assess the safety and feasibility of HBOC-201 in increasing adequate wound healing in patients with severe peripheral vascular disease who are undergoing lower limb amputation. The hypothesis is that HBOC-201 will pass through the partially occluded lesions in the peripheral arteries in the lower extremity and promote the wound healing process by delivering oxygen to the oxygen deprived tissues. This will reduce the incidence of lower limb wound complications at 60 days post-surgery and may reduce the incidence of a second amputation.

Timeline

Start
2006-05
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject HBOC-201 Protein / enzyme biologic 250 ml Intravenous
Comparator hydroxyethyl starch Other / unclassified 250 ml Intravenous